Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pegsunercept (PEG sTNF-RI)
pegsunercept · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pegsunercept (PEG sTNF-RI) | DRUG | - |
Inclusion Criteria: - Subjects who have completed 24 weeks of double-blind treatment in a previous protocol (20000201 or 20000198) - Females of childbearing potential and males must practice adequate contraception, in the judgement of the investigator, during the course of the study - The subject or...
Top 20 of 31 competitors
Pegsunercept is an investigational therapy that has been studied for the treatment of rheumatoid arthritis. It was evaluated in a Phase 2 clinical trial in adults with rheumatoid arthritis. It is not approved for any indication and remains in clinical development.
Pegsunercept targets TNF, tumor necrosis factor. It is a TNF inhibitor, meaning it is designed to block the activity of this inflammatory cytokine. The drug is also known as PEG sTNF-RI, reflecting its structure as a pegylated soluble TNF receptor type I.
Pegsunercept is being developed by Amgen Inc., which trades on the Nasdaq under the ticker AMGN. Amgen sponsored the Phase 2 trial of the drug in rheumatoid arthritis.
Pegsunercept is in Phase 2 development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 trial in rheumatoid arthritis has been completed.
Pegsunercept has been studied in one clinical trial, NCT00111423, titled Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI) in Subjects With Rheumatoid Arthritis (RA). This Phase 2 trial enrolled 216 adults and has been completed.
Yes, pegsunercept is also known as PEG sTNF-RI. The two names refer to the same investigational drug developed by Amgen for rheumatoid arthritis. PEG sTNF-RI describes the molecule as a pegylated soluble tumor necrosis factor receptor type I.